Skip to main content

Table 4 Enriched GO (MF) pathways of Safflower and Salvia compounds in MI and CI samples

From: Network pharmacology exploration reveals a common mechanism in the treatment of cardio-cerebrovascular disease with Salvia miltiorrhiza Burge. and Carthamus tinctorius L

Description

P value

p.adjust

qvalue

count

Heme binding

1.34E-08

1.74E-06

6.82E-07

6

Tetrapyrrole binding

2.09E-08

1.74E-06

6.82E-07

6

Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen

4.64E-08

2.15E-06

8.46E-07

6

Growth factor activity

5.19E-08

2.15E-06

8.46E-07

6

Cytokine receptor binding

1.21E-06

4.00E-05

1.57E-05

6

Receptor ligand activity

1.64E-06

4.55E-05

1.79E-05

7

Cytokine activity

8.28E-06

0.000175

6.87E-05

5

Monooxygenase activity

8.42E-06

0.000175

6.87E-05

4

Protease binding

2.50E-05

0.00038

0.000149

4

Growth factor receptor binding

2.50E-05

0.00038

0.000149

4

Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen

2.52E-05

0.00038

0.000149

3

Cofactor binding

3.10E-05

0.000428

0.000168

6

Iron ion binding

5.40E-05

0.00069

0.000271

4

Steroid hormone receptor activity

6.09E-05

0.000723

0.000284

3

Phosphatidylinositol-4,5-bisphosphate 3-kinase activity

9.32E-05

0.001032

0.000406

3

Phosphatidylinositol bisphosphate kinase activity

0.000106

0.0011

0.000433

3

Oxidoreductase activity, acting on NAD(P)H, heme protein as acceptor

0.000127

0.001198

0.000471

2

Phosphatidylinositol 3-kinase activity

0.00013

0.001198

0.000471

3

FMN binding

0.000148

0.001294

0.000509

2

Heme binding

1.34E-08

1.74E-06

6.82E-07

6